- INHIBITORS OF MLH1 AND/OR PMS2 FOR CANCER TREATMENT
-
The present invention relates to compounds of Formula (I) that target the MLH1 and/or PMS2 proteins that are components of the DNA Mismatch Repair (MMR) process: Formula (I) wherein R1, R2, R3, R4, R6
- -
-
-
- Highly selective recognition of a-chiral primary organoammonium ions by C3-symmetric peptide receptors
-
A straightforward synthesis of C3-symmet:ric, imidazole-containing, macrocyclic peptides with different binding arms is presented, The chirality of the backbone and the selection of adequate receptor arms make these systems highly selective receptors for α-chiral primary organoammonium ions. Furthermore, the receptors have the ability to discriminate between enantiomeric guests with selectivity ratios of up to 87:13, The binding constants and the selectivity ratios were estimated by standard 1H NMR titration techniques in CDCl3.
- Schnopp, Markus,Haberhauer, Gebhard
-
experimental part
p. 4458 - 4467
(2010/02/16)
-
- Farnesyl protein transferase inhibitors
-
Disclosed are compounds of the formula: wherein R8represents a cyclic moiety to which is bound an imodazolylalkyl group; R9represents a carbamate, urea, amide or sulfonamide group; and the remaining substituents are as defined herein. Also disclosed is a method of treating cancer and a method of inhibiting farnesyl protein transferase using the disclosed compounds.
- -
-
-
- Azastilbenes. 1. Synthesis, Characterization, and Structure
-
The synthesis of several symmetric and asymmetric azastilbenes is described, and their spectral characteristics (NMR, mass, UV, IR) are given.Four of them are new compounds, namely, 1,2-di(4-isoquinolyl)ethylene, 1-(3-pyridyl)-2-(2-pyrazinyl)ethylene, 1-(
- Vansant, J.,Smets, G.,Declercq, J. P.,Germain, G.,Meerssche, M. Van
-
p. 1557 - 1565
(2007/10/02)
-